Likewise, co-treatment of mice bearing BRAF V600E-driven melanoma with CSF-1R- and PD1-blocking antibodies increased efficacy when compared to single agent treatments [100], most likely due to the capacity of melanoma cell-derived CSF-1 to enhance TAM recruitment. The gene discussed is PDCD1; the disease is melanoma.